Walmart reshuffles merchandising roles
A series of merchandising and marketing moves announced at Walmart created several new positions and aligned the organization in the four core areas of general merchandise and replenishment; food, softlines and consumables; health and wellness; and Walmart.com, according to an internal announcement.
The changes follow the departure two months ago of former chief merchandising officer John Fleming and the reassignment of former Walmart U.S. president and CEO Eduardo Castro-Wright to a diminished role in global sourcing amid sagging sales at the U.S. stores division. COO Bill Simon assumed the president and CEO role, although a new chief merchant has yet to be named.
Duncan MacNaughton was named EVP consumable, health and wellness and Walmart.com after previously serving as chief merchandising officer for Walmart Canada. Scott Huff will serve as SVP consumables, and John Agwunobi will serve as president and SVP health and wellness, with Scott McCall filling the role of SVP health and wellness merchandising. The new position of senior director of planning, pricing and modular development was filled by Phillip Freehling.
John Westling will remain in his roles as EVP general merchandise and replenishment, with Laura Phillips and Mark Samuels filling new positions. Phillips was named SVP toys, seasonal and network planning after previously serving as VP/DMM toys. Samuels was named VP planning, pricing and modular development. In another move, former Sam’s Club merchant Seong Ohm, who left briefly for a stint at Seiyu in Japan, was named SVP of the home, hardlines and entertainment global merchandising center. Phillips, Samuels and Ohm all report to Westling.
Jack Sinclair remains in his role as EVP food, with Steve Breen and Bruce Nelson promoted to new roles. Breen was named SVP snacks and drinks, and Nelson was named VP planning, pricing and modular development. All fresh and packaged grocery has been consolidated under the leadership of Pam Kohn, who will serve as SVP of the global food and consumables global merchandise center.
The softlines area will be led by Andy Barron, who was promoted to EVP after previously serving as SVP store merchandise execution. Reporting to Barron in new roles are Anne Marie Kehoe, VP planning, pricing and modular development, and Michelle Gloeckler as SVP merchandise execution.
CPSC, Health Canada find no link between Pampers Dry Max and diaper rash
CINCINNATI The U.S. Consumer Product Safety Commission and Health Canada announced Friday that they have found no cause linking Pampers Dry Max diapers and reports of diaper rash and other skin conditions.
"We are thankful that the U.S. CPSC and Health Canada conducted their thorough reviews and have not identified any cause for concern with Pampers with Dry Max," said Jodi Allen, VP of Pampers. "Our heartfelt mission is always to care for and protect babies, and, as such, safety is, and will always be, our No. 1 priority. We hope that today’s announcement will reassure the millions of moms, dads and child caregivers who place their trust in Pampers and Dry Max every day. We thank our customers for their continued support and greatly value and appreciate the trust they place in us."
To help parents battle diaper rash, Pampers is sponsoring the distribution of comprehensive educational materials produced by the American Academy of Pediatrics that provide detailed information on the care and treatment of infant skin conditions, including diaper rash, according to Allen. The AAP materials are available as free brochures and will appear in the summer issue of AAP Healthy Children Magazine, as well as online at HealthyChildren.org and at Pampers.com.
Pfizer ends brain cancer drug development deal with Celldex
NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug’s developer Celldex Therapeutics.
Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.
Celldex will regain rights to the drug candidate on Nov. 1.